112 related articles for article (PubMed ID: 24674880)
21. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
[TBL] [Abstract][Full Text] [Related]
22. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
23. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
Hare TR; Gardell SJ
Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
[TBL] [Abstract][Full Text] [Related]
24. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
Urano T; Sakakibara K; Rydzewski A; Urano S; Takada Y; Takada A
Thromb Haemost; 1990 Feb; 63(1):82-6. PubMed ID: 2111051
[TBL] [Abstract][Full Text] [Related]
25. Iron and carbon monoxide attenuate Crotalus atrox venom-enhanced tissue-type plasminogen activator-initiated fibrinolysis.
Nielsen VG; Boyer LV; Matika RW; Amos Q; Redford DT
Blood Coagul Fibrinolysis; 2016 Jul; 27(5):511-6. PubMed ID: 26575490
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B.
Suzuki K; Muto Y; Fushihara K; Kanemoto K; Iida H; Sato E; Kikuchi C; Matsushima T; Kato E; Nomoto M; Yoshioka S; Ishii H
J Pharmacol Exp Ther; 2004 May; 309(2):607-15. PubMed ID: 14762098
[TBL] [Abstract][Full Text] [Related]
27. Clot lifespan model analysis of the effects of warfarin on thrombus growth and fibrinolysis: role of contact protein and tissue factor initiation.
Nielsen VG; Kirklin JK; Holman WL; Steenwyk BL
ASAIO J; 2009; 55(1):33-40. PubMed ID: 19092656
[TBL] [Abstract][Full Text] [Related]
28. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
Nielsen VG
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
[TBL] [Abstract][Full Text] [Related]
29. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
Soni H; Sharma A; Bhatt S; Jain MR; Patel PR
Pharmacology; 2008; 82(4):304-9. PubMed ID: 18936552
[TBL] [Abstract][Full Text] [Related]
30. Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.
Carr ME; Krishnamurti C; Alving BM
Thromb Haemost; 1992 Jan; 67(1):106-10. PubMed ID: 1615464
[TBL] [Abstract][Full Text] [Related]
31. Carbon monoxide releasing molecule-2 enhances coagulation and attenuates fibrinolysis by two mechanisms: insights gained with colloid dilution.
Cohen JB; Persaud JM; Malayaman SN; Nielsen VG
Blood Coagul Fibrinolysis; 2011 Jan; 22(1):60-6. PubMed ID: 21157300
[TBL] [Abstract][Full Text] [Related]
32. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
33. Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation.
Leaker MT; Brooker LA; Mitchell LG; Weitz JI; Superina R; Andrew ME
Transplantation; 1995 Jul; 60(2):144-7. PubMed ID: 7624956
[TBL] [Abstract][Full Text] [Related]
34. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
35. Carbon monoxide releasing molecule-2 attenuates the anticoagulant and amplifies the hypofibrinolytic effects of hypothermia in human plasma in vitro.
Nielsen VG; George SJ
Blood Coagul Fibrinolysis; 2011 Jan; 22(1):67-72. PubMed ID: 21157299
[TBL] [Abstract][Full Text] [Related]
36. Absence of inhibition by lipoprotein (a) inhibition of tPA induced thrombolysis in a patient's plasma milieu.
Lu H; Bruckert J; Soria J; Li H; de Gennes JL; Legrand A; Peynet J; Soria C
Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):513-6. PubMed ID: 1966796
[TBL] [Abstract][Full Text] [Related]
37. Recombinant tissue-type plasminogen activator-evoked hyperfibrinolysis is enhanced by acidosis and inhibited by hypothermia but still can be blocked by tranexamic acid.
Dirkmann D; Radü-Berlemann J; Görlinger K; Peters J
J Trauma Acute Care Surg; 2013 Feb; 74(2):482-8. PubMed ID: 23354242
[TBL] [Abstract][Full Text] [Related]
38. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
39. [Parameters related to fibrinolysis and their meanings].
Urano T; Suzuki Y
Rinsho Byori; 2011 Jul; 59(7):703-8. PubMed ID: 21874797
[TBL] [Abstract][Full Text] [Related]
40. Evidence that fibrinolytic changes in paediatric obesity translate into a hypofibrinolytic state: relative contribution of TAFI and PAI-1.
Semeraro F; Giordano P; Faienza MF; Cavallo L; Semeraro N; Colucci M
Thromb Haemost; 2012 Aug; 108(2):311-7. PubMed ID: 22740053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
